BusinessKura Oncology to Report First Quarter 2018 Financial ResultsBy Nasdaq OMXMay 1, 2018, 11:30 AM UTC
BusinessKura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AMLBy Nasdaq OMXOct 28, 2017, 4:30 PM UTC
